Although the small intestine accounts for 75% of the length of the digestive tract and 90% of the mucosal surface area, small bowel cancers are rare: \<5% of gastrointestinal cancers ([@bib29]). Small bowel adenocarcinoma (SBA) represents around 40% of small bowel cancers ([@bib25]; [@bib8]), with roughly the same incidence as neuroendocrine tumours. In the United States of America, the estimated incidence of SBA is 5300 new cases per year, with around 1100 deaths per year ([@bib23]). The EUROCARE data indicate an estimated 3595 new cases of SBA every year in Europe ([@bib13]). The duodenum is most frequently involved, followed by the jejunum and ileum ([@bib25]; [@bib8]; [@bib1]).

SBA carries a poor prognosis at all stages with a 5-year overall survival (OS) of 50--60% for stage I, 39--55% for stage II, 10--40% for stage III and 3--5% for stage IV ([@bib43]; [@bib12]; [@bib32]). So, the prognosis of SBA appears to be intermediary between those of colon and gastric cancer. Lymph node metastases are the main prognostic factor ([@bib43]; [@bib12]). There is no evidence to support the use of adjuvant chemotherapy in SBA, but it may improve prognosis in cases of invaded lymph nodes ([@bib34]). In advanced disease, oxaliplatin-based chemotherapy appears to give the best results, with a median OS of 17.8 months ([@bib46]).

Biological parameters have been studied in few SBA patients ([@bib3]), and some results are conflicting. Moreover, the prognostic value of biological factors or of differences in tumour phenotype according to the primary site has never been assessed in SBA in a large number of patients together with the main changes in biological alteration. The aim of this study was to investigate several candidate genes or their protein expression in the genetic pathway of SBA.

The *APC* gene acquires a truncated mutation in the majority of sporadic colorectal cancers (CRCs) and is also responsible for familial adenomatous polyposis in cases of germline mutation. The inactivation of APC protein leads to an accumulation of *β*-catenin in the nuclei. More rarely, the *β*-*CATENIN* gene acquires a gain-of-function mutation. These augmentations of *β*-catenin activity in both cases lead to increased proliferation of epithelial cells and are considered an early event in the majority of CRCs ([@bib6]).

P53 is a nuclear oncosuppressor protein that is involved in the maintenance of genomic integrity. Mutations in the p53 gene occur commonly in a wide range of cancers and result in overexpression of inactive p53 protein in the nuclei. P53 mutations are a late event in colorectal carcinogenesis ([@bib20]).

The *KRAS* gene codes for a GTPase involved in the signalling pathways of several tyrosine kinase receptors. A *KRAS* mutation has been described in around 40% of CRCs, mainly in codons 12 or 13. Moreover, *KRAS* mutations are predictive of the lack of efficacy of anti-EGFR antibody in treatment of metastatic CRC ([@bib26]).

HER2 is one of a family of human epidermal growth factor receptors (HERs). Gene amplification and overexpression of HER-2/neu have been reported in around 15% of gastric cancers. Treatment with trastuzumab, an anti-HER-2 antibody, results in prolonged survival in gastric cancer if HER-2 is overexpressed or amplified in tumour cells ([@bib5]).

Inactivation of the DNA mismatch repair (MMR) gene is characterised by tumour microsatellite instability ([@bib48]). Four MMR genes have been described---*MLH1*, *MSH2*, *MSH6* and *PMS2*---and could be mutated, resulting in the loss of protein expression assessed by immunohistochemistry ([@bib17]). The germline mutation of one of the MMR genes is responsible for Lynch syndrome and predisposes to SBA ([@bib10]). Loss of MLH1 protein function could also result from hypermethylation of the *MLH1* promoter and accounts for \>20% of cases of CRC in elderly patients ([@bib2]). A *BRAF* V600 E mutation is frequently associated with *MLH1* promoter methylation in sporadic colorectal carcinomas ([@bib22]).

We characterised the protein and/or gene expression of *β*-catenin, p53, HER-2, MMR, *KRAS* and *BRAF* in a large number of SBA tumours. We investigated their expression according to the small bowel segment and defined the prognostic value of each. The results of this large study have direct clinical implications as some of the proteins/genes investigated are potential therapeutic targets.

Patients and methods
====================

Study population and tumour samples
-----------------------------------

A previous AGEO study ([@bib46]; [@bib47]) identified a series of 154 consecutive patients treated for SBA in 13 hospitals from 1996 to 2008. Among these patients, 91 were excluded because tumour samples were unavailable, mainly because of an unresectable or metastatic tumour or because no biopsy sample remained. A total of 63 cases from 12 hospitals were included and reviewed by a gastrointestinal pathologist (MS) to confirm the diagnosis and tumour grade. The clinical and follow-up data were partially collected in the previous AGEO studies and completed for the purpose of the present study. Data include demographics, cancer treatment history, stage, lymph node invasion, tumour differentiation, predisposing disease or known genetic syndrome, recurrence and survival. Patients were enrolled in the study at all stages of the disease, but tumour samples in all cases were from the primary tumour.

This study was authorised by the ethics committee 'Ile de France II\' No. ID-RCB: 2008-A01058-47.

Immunohistochemical analysis
----------------------------

Briefly, 4-*μ*m sections from the paraffin-embedded tissue samples were cut onto silane-treated Super Frost slides (CML, Nemours, France) and left to dry at 37 °C overnight. The slides were deparaffinised in xylene and rehydrated in pure ethanol. Endogenous peroxidase was blocked using 3% hydrogen peroxide in methanol for 30 min. Before immunostaining, antigen retrieval was performed by immersing sections in citrate buffer (pH 6.0). Sections were then incubated for 15 min at room temperature with antibodies to MLH1 (dilution 1/70, clone G168-728, Pharmingen, San Diego, CA, USA), MSH2 (dilution 1/100, clone FE11, Calbiochem, Oncogene Research Products, Cambridge, MA, USA), MSH6 (dilution 1/100, clone 44, Becton Dickinson, Lexington, NC, USA), PMS2 (clone A16-4, 1 : 150 dilution, BD PharMingen, Le Pont de Claix, France), *β*-catenin (E-5; 1/250 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and p53 (clone BP53-12-1; 1/800 dilution; Biogenex, San Ramon, CA, USA). The Bond Polymer Refine Detection kit (Leica, Nanterre, France) was used as the detection system. Immunostaining of MLH1, MSH2, MSH6 and PMS2 in tumour cells was evaluated as positive or negative. Tumours were considered negative when there was a complete absence of nuclear staining of neoplastic cells in the presence of an internal positive control. Tumours were classified as p53-positive when \>50% of nuclei in the carcinomatous epithelium were immunostained, as previously described ([@bib40]). For *β*-catenin, nuclear staining was evaluated as present or absent, separately for each specimen ([@bib49]). Nuclear accumulation of *β*-catenin was considered to reflect Wnt pathway activation. The expression of HER2 was investigated by immunochemistry using the antibody A0485 (DAKO, Trappes, France; 1 : 500 dilution).

Fluorescent *in situ* hybridisation:
------------------------------------

Tumours overexpressing HER2 protein as noted by immunohistochemistry (score 3+) were tested by fluorescent *in situ* hybridisation (FISH) performed using the pharmDxTM test kit (Dako Denmark A/S, Glostrup, Denmark). An HER2:CEP17 ratio ⩾2 was taken to indicate amplification.

Determination of *MLH1* promoter methylation:
---------------------------------------------

The DNA methylation pattern of the *MLH1* promoter region was determined by methylation-specific PCR on bisulphite-treated DNA (1 *μ*g) with primer sequences used by [@bib37]. This technique was performed in cases of loss of MLH1 protein expression.

Molecular analysis
------------------

DNA was extracted from formalin-fixed paraffin-embedded samples. The seven most frequent mutations on codons 12 and 13 of *KRAS* were assessed as previously described ([@bib26]). *BRAF* V600E mutations were detected by allelic discrimination using TaqMan probes following the same protocol as for *KRAS* mutations. Probes and protocol are available on request. MSI status was assessed using five microsatellites (BAT25, BAT26, NR21, NR24, NR27), and the deficient MMR phenotype was assigned if ⩾2 microsatellites were unstable.

Statistical analysis
--------------------

For demographic and clinical characteristics, categorical variables were summarised as frequency and percentage and continuous variables as mean and s.d. Tumour characteristics were analysed according to tumour stage and primary site. The link between variables was assessed using the Fisher\'s exact test or the *χ*^2^ test, as appropriate.

OS was defined as the time from diagnosis (diagnosis of metastases in subgroup analysis for metastatic patients) to death by any cause. Recurrence-free survival (RFS) was defined as the time from surgery to first recurrence (local or distant) or death (from any cause). Patients alive at the date cutoff without recurrence were censored. OS and RFS were estimated using the Kaplan--Meier method and described by the median with its 95% confidence interval (CI). Survival curves were compared using the log-rank test. Median follow-up was calculated with the reverse Kaplan--Meier method.

All analyses were first performed among the whole population, then in stage I--III patients and finally among metastatic patients.

Univariate proportional hazards Cox models were used to estimate hazard ratio (HR) with its 95% CI and to select potential prognostic factors linked to different end points. Proportional hazards assumptions were tested using the Schoenfeld residuals. All significant variables observed in univariate analysis at a 10% level were included in multivariate analysis. A ratio of at least 10 events per variable was recommended for the development of a stable model.

From the final multivariate model, we computed the Akaike information criterion for goodness of fit and Harrell\'s C-statistic for discrimination (a Harrell\'s C index of 0.5 indicates no predictive discrimination and a Harrell\'s C index of 1.0 indicates perfect separation of patients).

All analyses were conducted with a two-sided *α* level of 5%, and data were analysed by using R software, Version 2.15.1 ([www.r-project.org/?](http://www.r-project.org/?)).

Results
=======

Clinicopathological characteristics of the patients
---------------------------------------------------

Sixty-three patients were enrolled in the study. Patient and tumour characteristics are summarised in [Table 1](#tbl1){ref-type="table"}. Ages of patients ranged from 29 to 85 years, with a median of 58 years.

All patients with stages I to III tumours underwent resection surgery. For the 19 patients with a stage I--II tumour, 9 (47%) had 1--7 lymph nodes assessed and 10 (53%) had \>7 lymph nodes assessed. For the 22 patients with a stage III tumour, 11 (50%) had 1--2 positive lymph nodes and 11 (50%) had ⩾3 positive lymph nodes. Among these 22 patients, 3 had an R1 or R2 resection. Among the 19 patients with an R0 resected stage III tumour, adjuvant chemotherapy was performed in 16 (84%) cases.

Palliative chemotherapy was performed in 43 patients (20 stage IV with synchronous metastases, 2 locally advanced unresectable tumours and 21 metachronous metastases). The first-line chemotherapy prescribed was 5-fluoruracil (5FU)+oxaliplatin in 23 (53%), 5FU+irinotecan in 7 (16%), 5FU+cisplatin in 5 (12%), 5FU monotherapy in 4 (9%), 5FU+irinotecan+bevacizumab in 3 (7%) and capecitabine in 1 (2%).

Tumour phenotyping
------------------

Sixty-three tumours were available for analysis. In some tumours, all the immunochemistry analyses were not conclusive. For molecular analysis, only a part of the population could be analysed due to tumour fixation in picric acid in 14 cases.

P53 expression was assessed in 62 cases. Overexpression was present in 26 (42%) of the cases ([Figure 1A](#fig1){ref-type="fig"}). There is no interaction between differentiation grade and p53 overexpression as 12 out of 27 (44%) of the well-differentiated tumours and 6 out of 13 (46%) of the poorly differentiated had an overexpression of p53. Only 2 out of 14 (14%) of dMMR tumours showed p53 overexpression.

*β*-Catenin expression was assessed in 61 cases. Nuclear staining for *β*-catenin was noted in 12 (20%) tumours ([Figure 1B and C](#fig1){ref-type="fig"}).

HER2 expression was assessed in 62 cases. Overexpression of HER (3+) was observed in two ileum tumours (3.2%) ([Figure 1D](#fig1){ref-type="fig"}). These two tumours were FISH-positive.

Tumour MMR status was determined by molecular analysis or immunohistochemistry (IHC). Defective MMR (dMMR) phenotype was defined as the presence of either high-level tumour DNA MSI (MSI-H) or as the loss of tumour MLH1, MSH2, MSH6 or PMS2 protein expression. Proficient MMR (pMMR) phenotype was defined by tumour DNA microsatellite stable status, low-level MSI (MSI-L) status or normal tumour MLH1, MSH2, MSH6 or PMS2 protein expression. The MMR phenotype was assessed by molecular analysis in 42 cases and by IHC in 51 cases (with expression of all four proteins analysable). Altogether MMR status was determined in 61 patients by one or two methods. No discordance between IHC and molecular analysis assays was observed. A dMMR phenotype was observed in 14 (23%) of the tumours. The median age of patients was 58 years in those with dMMR tumours and 57 years in those with pMMR tumours. In 8 of these 14 tumours, expression of at least one MMR protein was deficient. Four tumours had a concomitant loss of expression of MLH1 and PMS2, two tumours had a concomitant loss of expression of MSH2 and MSH6 and two tumours had a loss of expression of MSH6. Among the four tumours with loss of MLH1 expression, *MLH1* promoter methylation was determined in three. One of them had methylation of the *MLH1* promoter and was classified as likely sporadic. Two did not present any methylation of the promoter: one corresponded to Lynch syndrome and the other to a lack of history of familial cancer. The remaining six cases of dMMR tumours were identified by molecular analysis. Altogether, Lynch syndrome was suspected in 9 out of 14 (64%) patients with a dMMR tumour according to their family history or to MSH2 or MSH6 loss of expression. In the 52 remaining patients with sporadic tumours, dMMR tumours were seen in 5 (9.6%).

*KRAS* mutation was assessed in 49 patients. A mutation was founded in 21 (43%) of the tumours. The *KRAS* mutation involved codon 12 in 12 (57%) of the mutated cases, codon 13 in 6 (29%), codon 61 in 2 (10%) and codon 146 in one (5%). A *BRAF* V600E mutation was assessed in 40 patients. Only one tumour was mutated: this tumour had no *KRAS* mutation and a pMMR phenotype.

Tumour characteristics according to tumour stage
------------------------------------------------

Tumour phenotype was analysed according to stage in univariate analysis. A dMMR phenotype was significantly associated with a non-metastatic tumour (*P*=0.02) ([Table 2](#tbl2){ref-type="table"}). P53 overexpression varied significantly according to tumour stage.

Tumour characteristics according to primary site
------------------------------------------------

Tumour characteristics were analysed according to the primary site ([Table 3](#tbl3){ref-type="table"}). A dMMR phenotype was observed in 28% of tumours in both duodenum (9 out of 32) and jejunum (5 out of 32) and none in the ileum. Among the 13 tumours in the ileum, Crohn\'s disease was reported in 6 (46%) cases. The only two cases of tumours with HER2 overexpression were located in the ileum.

Survival analysis
-----------------

### Overall survival for all patients

The median follow-up was 72.7 months (95% CI: 59.2; 113.2 months). There were 39 deaths at the end of follow-up. The median OS was 36.6 months (95% CI: 26.9; 72.2 months). All the studied variables satisfied the proportional hazards assumption.

In univariate analysis, age, WHO PS, resection quality, stage and dMMR phenotype were significantly associated with OS duration. A trend for poor prognosis was observed in poorly differentiated tumours ([Table 4](#tbl4){ref-type="table"}). In multivariate analysis, only stage and WHO PS remained as independent prognostic factors ([Table 4](#tbl4){ref-type="table"}). Harrell\'s C index was equal to 0.718. A second model was tested excluding WHO PS due to missing data ([Table 4](#tbl4){ref-type="table"}), and the results were similar.

### RFS in stages I--III patients

The median follow-up was 63.6 months (95% CI: 47.8; NA months) and the median RFS was 57.8 months (95% CI: 42.3; NA months).

No significant prognostic factor of RFS was identified ([Table 5](#tbl5){ref-type="table"}). A trend for a worse prognosis was associated with pMMR phenotype and poorly differentiated tumours.

### Overall survival in stage IV patients

Thirty-four patients had died after a median follow-up of 69.5 months (95% CI: 54.1; NA months). The median OS was 20.5 months (95% CI: 14.6; 36.6 months). In univariate analysis, poor WHO PS, poor differentiation grade, synchronous metastasis and wild-type *KRAS* were associated with poor prognosis ([Table 6](#tbl6){ref-type="table"}). In multivariate analysis, only poor WHO PS and wild-type *KRAS* were independent factors for poor prognosis ([Figure 2](#fig2){ref-type="fig"}).

Discussion
==========

Our study of 63 cases is one of the largest to consider the clinical and biological characteristics of SBA. We provide molecular and immunophenotypic descriptions of p53, *β*-catenin, MMR, *KRAS*, *BRAF* and HER2, and we have assessed the frequency of abnormalities according to the small bowel segment and assessed the prognostic value of all the clinical and biological characteristics.

The clinical characteristics of the patients enrolled in our study are comparable with those in other large studies on SBA and show that in most cases the primary site is duodenal ([@bib12]; [@bib8]; [@bib32]; [@bib1]) and around 20% of predisposing disease ([@bib1]).

Overexpression of p53 was detected in 26 of 62 cancers (42%). Ours is the largest study to have determined p53 expression in SBA. Our results are in line with those of [@bib4] and [@bib42], who found p53 overexpression in 8 out of 15 (53.3%) and 14 out of 27 (40.7%) cases, respectively, but not those of [@bib44], who report an overexpression in 5 of 21 (24%) SBA cases. Our results support a role of p53 mutation in 40--50% of SBA cases, as in colorectal or gastric carcinogenesis ([@bib49]; [@bib7]). There was no variation of p53 expression according to the small bowel segment or tumour grade. It should be pointed out that p53 overexpression is a rare event in the case of dMMR tumours, as in colorectal carcinogenesis ([@bib31]). Surprisingly, p53 overexpression was significantly more frequent in stages I--II tumours than in stage III tumours. This result should be confirmed in a larger number of tumours.

Abnormal accumulation of *β*-catenin in the nuclei was observed in 12 of 61 (20%) tumours assessed. In the literature reports, nuclear expression of *β*-catenin ranges from 2 out of 27 (7.4%) ([@bib42]), 2 out of 21 (23%) ([@bib9]), 79 out of 194 (40.7%) ([@bib24]) to 10 out of 21 (48%) ([@bib44]). One study reported a shorter survival in the case of combined loss of E-cadherin and aberrant *β*-catenin expression ([@bib24]). The accumulation of *β*-catenin could occur either in the case of *APC* gene mutation preventing *β*-catenin degradation or by gain-of-function mutations ([@bib28]; [@bib9]). A nuclear accumulation of *β*-catenin was observed in the same range of around 20% of tumours in gastric cancer ([@bib21]). Our results suggest that the Wnt pathway has a much less important role in SBA than in colorectal carcinogenesis in which nuclear accumulation of *β*-catenin is seen in around 80% of tumours ([@bib18]).

We found a *KRAS* mutation in 21 out of 49 (43%) tumours, compared with 8 out of 15 (53.3%) ([@bib4]) and 12 out of 21 (57%) ([@bib9]) in literature reports, range of mutation rates similar to that in CRC and higher than in gastric cancer. Nevertheless, two older studies reported *KRAS* mutation rates of only 5 out of 20 (25%) ([@bib27]) and 4 out of 28 (14%) ([@bib45]). The latter study found *KRAS* mutations only in duodenal tumours, in contrast to our results showing no difference in *KRAS* mutation rate according to the small intestine segment. A recent large study on resected stages I--III duodenal adenocarcinomas revealed a *KRAS* mutation rate of 34.6% and KRAS G\>A mutation carriers were at increased risk of distant relapse and had a significantly shorter OS ([@bib14]). Be that as it may, the *KRAS* mutation rate observed in our study and other studies justifies routine preliminary *KRAS* determination to identify the patient population in which anti-EGFR therapy could be effective.

Reported frequencies of HER2 overexpression in SBA vary widely: 9 out of 16 cases in duodenal tumours in a 1996 study by [@bib50] and only 1 out of 54 cases in SBA in a recent study ([@bib35]). The latter result is in line with ours showing that HER2 expression is a rare event in SBA. We found no HER2 expression in duodenal tumours, in contrast to the findings [@bib50], a discrepancy that could be explained by a lack of specificity of the antibody used by these authors. It should be pointed out that in our study the expression of HER2 was confirmed by FISH in the two cases. Moreover, a recent study revealed that genome-wide copy number profiles of most SBAs overlap primarily with colorectal carcinomas rather than gastric adenocarcinomas ([@bib15]). In the study of [@bib15], ERBB2 amplification is a rare event observed in only 1 out of 27 SBA that cluster with colorectal cancer and not gastric cancer.

The frequency of dMMR tumours in SBA reported in the literature ranges from 5% to 35% when appropriate methods are applied ([@bib27]; [@bib44]; [@bib39]; [@bib42]; [@bib11]; [@bib49]; [@bib35]), probably because of a selection bias in favour of Lynch syndrome patients in the studies with the highest frequency of dMMR tumours. In our study, a dMMR phenotype was observed in 14 out of 61 (23%) tumours. In a previous study, when Lynch syndrome was excluded, a dMMR was found in only 1 out of 21 (5%) tumours ([@bib44]). In our study, when suspected Lynch syndrome patients were excluded the frequency of dMMR tumours dropped to 9%. In previous studies, the dMMR phenotype was associated with young age ([@bib39]; [@bib35]). This was not observed in our study. In CRC, the relation between dMMR status and age is complex as young age is associated with Lynch syndrome, but on the other hand advanced age is associated with a high frequency of dMMR tumours due to hypermethylation of the *MLH1* promoter ([@bib2]). In the latter case, a *BRAF* mutation is frequently observed, but in our study only one *BRAF* mutation was observed in a pMMR tumour. Moreover, MLH1 hypermethylation was infrequent. So, our results suggest that the majority of SBA dMMR tumours are not related to a methylation mechanism but to a germline mutation.

In accordance with the result in CRC ([@bib41]), dMMR status was associated with an early stage in the present study. A dMMR phenotype was observed more frequently among proximal (duodenum and jejunum) than distal tumours. No dMMR tumour was observed in the ileum. This result was not previously reported and suggests that proximal tumours are more likely due to Lynch syndrome than are distal tumours. Moreover, ileal tumours were related to Crohn\'s disease in 46% of the cases. This is in accordance with a previous study on 20 SBAs related to Crohn\'s disease showing that the tumour occurs mainly in the ileum ([@bib36]).

Poor prognosis of SBA is associated with advanced age, pT4 tumour stage, poorly differentiated tumour, positive resection margins, lymphovascular invasion, lymph node invasion and a low number of recovery lymph nodes ([@bib16]; [@bib30]; [@bib33]). Several large studies suggest that duodenal tumours have a worse prognosis than jejunal or ileal tumours ([@bib19]; [@bib12]; [@bib33]). Similarly to what was reported in a previous study ([@bib35]), we did not find such a prognostic value of primary site.

Prognostic factors associated with a better overall survival were early tumour stage, R0 resection, WHO PS 0-1 and dMMR tumour in univariate analysis and tumour stage and WHO PS in multivariate analysis. A good prognostic value of dMMR is well documented in colorectal tumours ([@bib41]). In contrast, a previous study in 54 cases of SBA did not report that MMR status is of prognostic value ([@bib35]).

In resected tumours, no significant prognostic factors for recurrence were observed. Nevertheless, a trend for a protective effect of dMMR and well or moderately differentiated tumours was observed. This trend should be studied in a larger number of patients.

In a metastatic setting, the factors predictive of good survival in multivariate analysis were WHO PS 0-1 and KRAS mutation. This result is in conflict with results in CRC where KRAS mutation had no prognostic value in a metastatic setting ([@bib38]). It should be pointed out though that none of the patients in our study received an anti-EGFR treatment as first-line chemotherapy.

In conclusion, our results show that SBA has some carcinogenesis pathways in common with CRC. P53 alteration and *KRAS* mutation are in the same range as in CRC. Nevertheless, some major differences should be pointed out, and the trigger of carcinogenesis seems to be different from that in CRC. A predisposing disease is more frequent than in CRC. The dMMR phenotype frequency appears comparable to that in CRC, but mainly in a context of Lynch syndrome and rarely secondary to *HMLH1* promoter methylation, in contrast to CRC. Moreover, the involvement of the Wnt pathway leading to *β*-catenin accumulation is less frequent in SBA than in CRC. Moreover, our results suggest that the dMMR phenotype is more frequently observed at an early stage and for duodenal and jejunal adenocarcinoma and had a prognostic value in resected tumours. Surprisingly, *KRAS* mutation is associated with a good prognosis in a metastatic setting. These results should be confirmed in a larger study. Altogether, our results suggest that SBA should be treated more like CCR than like gastric adenocarcinoma.
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![**Representative immunohistochemical staining.** (**A**) Positive p53 immunostaining ( × 200 magnification); (**B**) in normal small intestinal epithelium, *β*-catenin was expressed exclusively on the plasma membrane, with no nuclear positivity ( × 400 magnification); (**C**) tumour cells with aberrant nuclear staining of *β*-catenin ( × 400 magnification); and (**D**) tumour cells strongly expressing HER2 (scoring 3+) ( × 400 magnification). Amplification of *HER2* was observed in this case.](bjc2013677f1){#fig1}

![Kaplan--Meier survival plot according to *KRAS* status among patients with stage IV disease.](bjc2013677f2){#fig2}

###### Patient and tumour characteristics

  **Characteristic**                **No. (%) of patients (*****n*****=63)**
  -------------------------------- ------------------------------------------
  **Sex**                          
  Men                                               33 (52)
  Women                                             30 (48)
  Predisposing disease                              17 (27)
  Crohn\'s disease                                   8 (12)
  Lynch syndrome                                     6 (9)
  Familial adenomatous polyposis                     2 (3)
  Coeliac disease                                    2 (3)
  **Tumour stage at diagnosis**    
  I--II                                             19 (30)
  III                                               22 (35)
  IV                                                20 (32)
  Locally advanced                                   2 (3)
  **Primary tumour site**          
  Duodenum                                          32 (51)
  Jejunum                                           18 (29)
  Ileum                                             13 (20)
  **Histological grade**           
  Well differentiated                               27 (43)
  Moderately differentiated                         23 (36)
  Poorly differentiated                             13 (21)

###### Tumour phenotype according to stage

  **Tumour characteristic**                            **Stages I--II,** ***n*****=19 (30%)**   **Stage III,** ***n*****=22 (35%)**   **Stage IV,** ***n*****=20 (32%)**   ***P*** **value**
  ---------------------------------------------------- ---------------------------------------- ------------------------------------- ------------------------------------ -------------------
  Poorly differentiated (*n*=13)                       1 (8%)                                   6 (46%)                               6 (46%)                              0.10
  P53 overexpression (*n*=26)                          14 (54%)                                 3 (11%)                               9 (35%)                              \<0.001
  Abnormal *β*-catenin (*n*=12)                        5 (42%)                                  3 (25%)                               4 (33%)                              0.61
  dMMR phenotype (*n*=14)                              4 (29%)                                  9 (64%)                               1 (7%)                               0.02
  Mutated *KRAS* (*n*=21[a](#t2-fn2){ref-type="fn"})   5 (24%)                                  8 (38%)                               7 (33%)                              0.79

Abbreviation: dMMR=mismatch repair deficiency.

One tumour of undetermined stage was locally advanced.

###### Tumour characteristics according to the primary site

  **Tumour characteristic**        **Duodenum,** ***n*****=32 (51%)**   **Jejunum,** ***n*****=18 (29%)**   **Ileum,** ***n*****=13 (20%)**   ***P*****-value**
  -------------------------------- ------------------------------------ ----------------------------------- --------------------------------- -------------------
  Stages I--II (*n*=19)            8 (42%)                              7 (37%)                             4 (21%)                            
  Stage III (*n*=22)               13 (59%)                             5 (23%)                             4 (18%)                           0.81
  Stage IV (*n*=20)                9 (45%)                              6 (30%)                             5 (25%)                            
  Poorly differentiated (*n*=13)   5 (38%)                              3 (24%)                             5 (38%)                           0.23
  P53 overexpression (*n*=26)      13 (50%)                             8 (31%)                             5 (19%)                           0.89
  Abnormal *β*-catenin (*n*=12)    4 (33%)                              3 (25%)                             5 (42%)                           0.16
  dMMR phenotype (*n*=14)          9 (64%)                              5 (36%)                             0 (0%)                            0.07
  Mutated *KRAS* (*n*=21)          12 (57%)                             6 (29%)                             3 (14%)                           0.73
  HER2 expression 2+ (*n*=2)       0 (0%)                               0 (0%)                              2 (100%)                          ---

Abbreviation: dMMR=mismatch repair deficiency.

###### Prognostic factors according to overall survival in all patients

                                             **Univariate analyses**                      
  ----------------------------------------- ------------------------- ------ ------------ ---------
  **Sex**                                                                                 
  Male vs female                                      39/61           1.19   0.62--2.30     0.61
  **Age in years**                                                                        
  Continuous                                          39/61           0.98   0.96--1.00     0.06
  \>65 vs⩽65                                          39/61           0.65   0.32--1.32     0.23
  **WHO PS**                                                                              
  2 *vs* 0--1                                         32/38           3.4    1.47--7.97    \<0.01
  **Disease stage**                                                                       
  Stage III *vs* stages I and II                      37/59           1.20   0.45--3.24     0.72
  Stage IV *vs* stages I and II                       37/59           6.97   2.69--18.1    \<0.001
  **Tumour differentiation**                                                              
  Poorly *vs* well and moderately                     39/61           1.94   0.90--4.19     0.09
  **Primary site**                                                                        
  Jejunum *vs* duodenum                               39/61           0.85   0.38--1.86     0.68
  Ileum *vs* duodenum                                 39/61           1.43   0.65--3.14     0.37
  **Quality of resection**                                                                
  R1 *vs* R0                                          34/56           2.60   0.88--7.71     0.08
  R2 *vs* R0                                          34/56           2.65   1.05--6.69     0.04
  **Baseline CA19-9 (IU** **ml**^**−1**^)                                                 
  \>37 *vs*⩽37                                        28/34           1.69   0.49--5.77     0.40
  **Baseline CEA (ng** **ml**^**−1**^)                                                    
  5 *vs*⩽5                                            33/40           0.92   0.32--2.65     0.88
  ***β*****P53**                                                                          
  Overexpression *vs* normal                          38/60           0.92   0.48--1.80     0.82
  ***β*****-Catenin**                                                                     
  Abnormal *vs* normal                                38/60           0.96   0.43--2.11     0.91
  **MMR phenotype**                                                                       
  dMMR *vs* pMMR                                      38/59           0.29   0.10--0.85     0.02
  ***KRAS*** **status**                                                                   
  Mutated *vs* wild                                   30/48           0.72   0.35--1.48     0.36

                                   **Multivariate analyses**                 
  -------------------------------- --------------------------- ------------- ---------
  **WHO PS**                                                                 
  2 *vs* 0--1                      7.07                        2.25--22.17   \<0.001
  **Disease stage**                                                          
  Stage III *vs* stages I and II   0.92                        0.22--3.89    0.90
  Stage IV *vs* stages I and II    6.09                        1.68--22.16   \<0.01
  **MMR phenotype**                                                          
  dMMR *vs* pMMR                   1.48                        0.39--5.57    0.56

                                   **Multivariate analyses excluding PS status**                 
  -------------------------------- ----------------------------------------------- ------------- ---------
  **Disease stage**                                                                              
  Stage III *vs* stages I and II   1.51                                            0.53--4.33    0.44
  Stage IV *vs* stages I and II    6.78                                            2.57--17.92   \<0.001
  **MMR phenotype**                                                                              
  dMMR *vs* pMMR                   0.44                                            0.13--1.55    0.20

Abbreviations: CEA=carcinoembryonic antigen; CI=confidence interval; dMMR=mismatch repair deficiency; Evts=events; HR=hazard ratio; pMMR=proficient mismatch repair; PS=performance status; pts=patients; WHO=World Health Organisation.

Log-rank test.

###### Prognostic factors for patients with stages I--III disease according to recurrence-free survival

                                                                                   **Univariate analyses**                       
  -------------------------------------------------------------------------------- ------------------------- ------ ------------ ------
  **Sex**                                                                                                                        
  Male *vs* female                                                                 17/34                     1.38   0.51--3.74   0.53
  **Age in years**                                                                                                               
  \>65 *vs* ⩽65                                                                    17/34                     0.77   0.29--2.0    0.59
  **WHO PS**                                                                                                                     
  2 *vs* 0--1                                                                      12/14                     1.20   0.25--5.82   0.82
  **Disease stage**                                                                                                              
  Stage III *vs* stages I and II                                                   17/34                     0.73   0.28--1.90   0.51
  **Tumour differentiation**                                                                                                     
  Poorly *vs* well and moderately differentiated                                   17/34                     1.37   0.39--4.81   0.63
  **Primary site**                                                                                                               
  Jejunum *vs* duodenum                                                            17/34                     1.09   0.35--3.34   0.89
  Ileum *vs* duodenum                                                              17/34                     1.20   0.36--4.01   0.76
  **Baseline CA19-9 (IU ml**^**−1**^)                                                                                            
  \>37 *vs* ⩽37                                                                    10/11                     1.11   0.13--9.29   0.93
  **Baseline CEA (ng ml**^**−1**^)                                                                                               
  \>5 *vs* ⩽5                                                                      12/14                     2.71   0.30--24.4   0.37
  Number of invaded lymph nodes for stage III[b](#t5-fn3){ref-type="fn"}           17/34                     1.05   0.90--1.23   0.54
  Number of analysed lymph nodes for stage III[b](#t5-fn3){ref-type="fn"}          16/32                     0.98   0.91--1.04   0.47
  Ratio of invaded/analysed lymph nodes for stage III[b](#t5-fn3){ref-type="fn"}   16/32                     3.60   0.61--21.4   0.16
  **Adjuvant chemotherapy**                                                                                                       
  No *vs* yes                                                                      17/34                     0.89   0.31--2.53   0.83
  FOLFOX *vs* 5U                                                                   12/22                     0.41   0.12--1.38   0.15
  **P53**                                                                                                                        
  Overexpression *vs* normal                                                       17/34                     1.04   0.40--2.70   0.94
  ***β*****-Catenin**                                                                                                            
  Abnormal *vs* normal                                                             16/33                     0.92   0.30--2.87   0.89
  **MMR phenotype**                                                                                                              
  dMMR *vs* pMMR                                                                   17/33                     0.41   0.13--1.28   0.12
  ***KRAS*** **status**                                                                                                          
  Mutated *vs* wild                                                                11/26                     0.83   0.24--2.84   0.76

Abbreviations: CI=confidence interval; dMMR=mismatch repair deficiency; Evts=events; HR=hazard ratio; pMMR=proficient mismatch repair; PS=performance status; pts=patients; WHO=World Health Organisation.

Log-rank test.

Continuous variable.

###### Prognostic factors for metastatic patients according to overall survival

                                                    **Univariate analyses**                      
  ------------------------------------------------ ------------------------- ------ ------------ ----------
  **Sex**                                                                                        
  Female *vs* male                                           34/41           1.08   0.54--2.17   0.82
  **Age in years**                                                                               
  Continuous                                                 34/41           0.99   0.97--1.02   0.64
  \>65 *vs* ⩽65                                              34/41           1.17   0.51--2.63   0.70
  **WHO PS**                                                                                     
  2 *vs* 0--1                                                29/34           8.52   2.92--24.9   \<0.0001
  **Tumour differentiation**                                                                     
  Poorly *vs* well and moderately differentiated             34/41           2.70   1.13--6.46   0.03
  **Primary site**                                                                               
  Jejunum *vs* duodenum                                      34/41           0.60   0.25--1.40   0.24
  Ileum *vs* duodenum                                        34/41           1.34   0.57--3.12   0.50
  **Baseline CA19-9 (IU ml**^**−1**^)                                                            
  \>37 *vs* ⩽37                                              25/30           2.13   0.61--7.37   0.23
  **Baseline CEA (ng ml**^**−1**^)                                                               
  \>5 *vs* ⩽5                                                30/36           0.84   0.29--2.43   0.74
  **Palliative chemotherapy**                                                                    
  No *vs* yes                                                34/41           0.67   0.09--5.01   0.69
  **Dual therapy**                                                                               
  No *vs* yes                                                33/39           4.27   0.85--21.6   0.08
  **Metastatic**                                                                                 
  Synchronous *vs* metachronous                              34/41           2.35   1.07--5.19   0.03
  **P53**                                                                                        
  Overexpression *vs* normal                                 33/40           0.96   0.47--1.95   0.9
  ***β*****-Catenin**                                                                            
  Abnormal *vs* normal                                       34/41           1.05   0.45--2.43   0.91
  **MMR phenotype**                                                                              
  dMMR *vs* pMMR                                             33/40           0.52   0.15--1.79   0.30
  ***KRAS*** **status**                                                                          
  Mutated *vs* wild                                          26/30           0.35   0.14--0.83   0.02

                          **Multivariate analyses**                
  ----------------------- --------------------------- ------------ ---------
  **WHO PS**                                                       
  2 *vs* 0--1             14.6                        0.19--66.5   \<0.001
  ***KRAS*** **status**                                            
  Mutated vs wild         0.37                        0.15--0.96   0.04

Abbreviations: CI=confidence interval; dMMR=mismatch repair deficiency; Evts=events; HR=hazard ratio; pMMR=proficient mismatch repair; PS=performance status; pts=patients; WHO=World Health Organisation.

Log-rank test.
